Prospective Clinical Trials Using a Pharmacogenetic/Pharmacogenomic Approach

References

• Peters GJ, Schornagel J, Milano GA. Clinical pharmaco-kinetics of antimetabolites. Cancer Surv 1993; 17: 123–156.
   PubMedGoogle Scholar
• van Kuilenburg AB. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer 2004; 40: 939–950.
   PubMed Web of Science ®Google Scholar
• Gamelin E, Boisdron-Celle M, Delva R, Regimbeau C, Cailleux PE, Alleaume C, et al. Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucov-orin: results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients. J Clin Oncol 1998; 16: 1470-1478.
   Google Scholar
• Lu Z, Zhang R, Diasio RB. Population characteristics of hepatic dihydropyrimidine dehydrogenase activity, a key meta-bolic enzyme in 5-fluorouracil chemotherapy. Clin Pharmacol Ther 1995; 58: 512–522.
   PubMed Web of Science ®Google Scholar
• Salonga D, Danenberg KD, Johnson M, Metzger R, Groshen S, et al. Colorectal tumors responding to 5-fluo-rouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phospho-rylase. Clin Cancer Res 2000; 6, 1322–1327.
   PubMed Web of Science ®Google Scholar
• Popat S, Matakidou A, Houlston RS. Thymidylate syn-thase expression and prognosis in colorectal cancer: a system-atic review and meta-analysis. J Clin Oncol 2004; 22: 529–536.
   PubMed Web of Science ®Google Scholar
• Spears CP, Gustavsson BC, Berne M, Frosing R, Berstein L, Hays AA. Mechanisms of innate resistance to thymidylate synthase inhibition after 5-fluorouracil. Cancer Res 1988; 48: 5894-5900.
   Google Scholar
• Van Triest B, Peters CJ. Thymidylate synthase: a target for combination therapy and determinant of chemotherapeutic response in colorectal cancer. Oncology 1999; 57: 179–194
   PubMed Web of Science ®Google Scholar
• Peters CJ, Van der Wilt CL, Van Groeningen CJ, Meijer S, Smid K, Pinedo HM. Thymidylate synthase inhibi-tion after administration of 5-fluorouracil with or without leu-covorin; implications for treatment with 5-fluorouracil. J Clin Oncol 1994; 12: 2035-2042.
   Google Scholar
• Swain SM, Lippman ME, Egan EF, Drake JC, Steinberg SM, Allegra CJ. Fluorouracil and high-dose leucov-orin in previously treated patients with metastatic breast can-cer. J Clin Oncol 1989; 7: 890–899.
   PubMed Web of Science ®Google Scholar
• Johnston PG, Fisher ER, Rockette HE, Fisher B, Wolmark N, Drake JC, et al. The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemothera-py in patients with rectal cancer. J Clin Oncol 1994; 12: 2640–2647.
   PubMed Web of Science ®Google Scholar
• Backus HHJ, Van Riel JMGH, Van Groeningen CJ, Vos W, Dukers DF, Bloemena E, et al. Rb, mc1-1 and p53 expression correlate with clinical outcome in patients with liver metastases from colorectal cancer. Ann. Oncol 2001; 12: 779–785.
   PubMed Web of Science ®Google Scholar
• Horikoshi T, Danenberg KD, Stadlbauer TH, Volkenandt M, Shea LC, Aigner K, et al. Quantitation of thymidylate synthase, dihydrofolate reductase, and DT-diaphorase gene expression in human tumors using the poly-merase chain reaction. Cancer Res 1992; 52: 108–16.
   PubMed Web of Science ®Google Scholar
• Van Triest B, Loftus BM, Pinedo HM, Backus HH, Schoenmakers P, Telleman F, et al. Thymidylate synthase expression in patients with colorectal carcinoma using a poly-clonal thymidylate synthase antibody in comparison to the TS 106 monoclonal antibody. J. Histochem Cytochem 2000; 48: 755–760.
   PubMed Web of Science ®Google Scholar
• Findlay MP, Cunningham D, Morgan G, Clinton S, Hardcastle A, Aherne GW. Lack of correlation between thymidylate synthase levels in primary colorectal tumours and subsequent response to chemotherapy. Br J Cancer 1997; 75: 903–909.
   PubMed Web of Science ®Google Scholar
• Barrat PL, Seymour MT, Stenning SP, Georgiades I, Walker C, Birbeck K, et al. DNA markers predicting benefit from adjuvant fluorouracil in patients with coon cancer: a mol-ecular study. Lancet 2002; 360: 1381–1391.
   PubMed Web of Science ®Google Scholar
• Meyers M, Wagner MW, Hwang HS, Kinsella TJ, Boothman DA. Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses. Cancer Res 2001; 61: 5193-5201.
   Google Scholar
• Van Triest B, Pinedo HM, Giaccone G, Peters CJ. Downstream molecular determinants of response to 5-fluo-rouracil and antifolate thymidylate synthase inhibitors. Ann Oncol 2000; 11: 385–391
   PubMed Web of Science ®Google Scholar
• Allegra CJ, Paik S, Colangelo LH, Parr AL, Kirsch I, Kim G, et al. Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study. J Clin Oncol 2003; 21: 241–250.
   PubMed Web of Science ®Google Scholar
• Wang TL, Diaz LA Jr, Romans K, Bardelli A, Saha S, Galizia G, et al. Digital karyotyping identifies thymidylate syn-thase amplification as a mechanism of resistance to 5-fluo-rouracil in metastatic colorectal cancer patients. Proc Natl Acad Sci USA 2004; 101: 3089-3094.
   Google Scholar
• Mauritz R, Beumer IJ, Marsh S, McLeod HL, Smid K, Van Groeningen CJ, et al. Polymorphism of the thymidylate synthase gene and thymidylate synthase levels in colon cancer cell lines and different tissues of colorectal cancer patients. Nucleosides, Nucleotides & Nucleic Acids 2004, in press
   Google Scholar
• Marsh S, McKay JA, Cassidy J, McLeod HL. Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer. Int J Oncol 2001; 19: 383–386.
   PubMed Web of Science ®Google Scholar
• Iacopetta B, Grieu F, Joseph D, Elsaleh H. A polymor-phism in the enhancer region of the thymidylate synthase pro-moter influences the survival of colorectal cancer patients treated with 5-fluorouracil. Br J Cancer 2001; 85: 827–831.
   PubMed Web of Science ®Google Scholar
• Villafranca E, Okruzhnov Y, Dominguez MA, Garcia-Foncillas J, Azinovic I, Martinez E, et al. Polymorphisms of the repeated sequences in the enhancer region of the thymidy-late synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer. J Clin Oncol 2001; 19, 1779–1786,
   PubMed Web of Science ®Google Scholar
• Kawakami K, Watanabe G. Identification and functional analysis of single nucleotide polymorphism in the tandem repeat sequence of thymidylate synthase gene. Cancer Res 2003; 63: 6004–6007
   PubMed Web of Science ®Google Scholar
• Sobrero AF, Aschele C, Bertino JR. Fluorouracil in col-orectal cancer—a tale of two drugs: implications for biochemi-cal modulation. J Clin Oncol 1997; 15: 368–381.
   PubMed Web of Science ®Google Scholar
• Van Laar JAM, Van der Wilt CL, Smid K, Noordhuis P, Rustum YM, Pinedo HM, Peters CJ. Therapeutic efficacy of fluoropyrimidines depends on the duration of thymidylate synthase inhibition in the murine Colon 26-b carcinoma tumor model. Clin Cancer Res 1996; 2: 1327–1333.
   PubMed Web of Science ®Google Scholar
• Peters CJ, Backus HHJ, Freemantle S, van Triest B, Codacci-Pisanelli G, van der Wilt CL, et al. Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. Biochim Biophys Acta 2002; 1587: 194–205.
   PubMed Web of Science ®Google Scholar
• Codacci-Pisanelli G, Van der Wilt CL, Smid K, Noordhuis P, Voorn D, Pinedo HM, Peters CJ. High-dose 5-fluorouracil with uridine-diphosphoglucose rescue increases thymidylate synthase inhibition but not 5-fluorouracil incorporation into RNA in murine tumors. Oncology 2002; 62: 363–370.
   PubMed Web of Science ®Google Scholar
• Noordhuis P, Holwerda U, Van Der Wilt CL, Van Groeningen CJ, Smid K, Meijer S, et al. 5-Fluorouracil incor-poration into RNA and DNA in relation to thymidylate syn-thase inhibition of human colorectal cancers. Ann Oncol 2004; 15: 1025-1032.
   Google Scholar
• Aschele C, Debernardis D, Bandelloni R, Cascinu S, Catalano V, Giordani P, et al. Thymidylate synthase protein expression in colorectal cancer metastases predicts for clinical outcome to leucovorin-modulated bolus or infusional 5-fluo-rouracil but not methotrexate-modulated bolus 5-fluorouracil. Ann Oncol 2002; 13: 1882-1892,
   Google Scholar
• Van Triest B, Pinedo HM, Blaauwgeers JL, van Diest PJ, Schoenmakers PS, Voorn DA, et al. Prognostic role of thymidylate synthase, thymidine phosphorylase/platelet-derived endothelial cell growth factor, and proliferation markers in col-orectal cancer. Clin Cancer Res, 2000; 6, 1063–1072.
   PubMed Web of Science ®Google Scholar
• De Bruin M, Smid K, Laan AC, Noordhuis P, Fukushima M, Hoekman K, et al. Rapid disappearance of deoxyribose-l-phosphate in platelet derived endothelial cell growth factor/thymidine phosphorylase overexpressing cells. Biochem Biophys Res Comm 2003; 301; 675–679.
   PubMed Web of Science ®Google Scholar
• Peters GJ. Relative role of 5-fluorouracil activation and inactivation pathways in its cytotoxic effects; Preclinical and clinical modulation. Chapter 1 from: Anticancer Drug Development Guide: Fluoropyrimidines in Cancer Therapy (Ed. Y.M. Rustum), Humana Press Inc., Totowa, NJ; 2002: 1-27.
   Google Scholar
• Komatsu T, Yamazaki H, Shimada N, Nakajima M, Yokoi T. Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos 2000; 28: 1457-1463.
   Google Scholar
• Peters GJ, Noordhuis P, Van Groeningen CJ, Giaccone G, Holwerda U, Voorn D, et al. The effect of food on the pharmacokinetics of 5-1 after single oral administration to patients with solid tumors. Clin Cancer Res 2004; 10: 4072-4076.
   Google Scholar
• Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999; 286: 487–491.
   PubMed Web of Science ®Google Scholar
• Houghton PJ, Germain GS, Harwood FC, Schuetz JD, Stewart CF, Buchdunger E, Traxler P. Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and revers-es resistance to topotecan and SN-38 in vitro. Cancer Res 2004; 64: 2333-2337.
   Google Scholar
• Mini E, Trave F, Rustum YM, Bertino JR. Enhancement of the antitumor effects of 5-fluorouracil by folinic acid. Pharmacol Ther 1990; 47: 1–19.
   PubMed Web of Science ®Google Scholar
• Peters GJ, Van Groeningen CJ. Clinical relevance of biochemical modulation of 5-fluorouracil. Ann Oncol 1991; 2: 469–480.
   PubMed Web of Science ®Google Scholar
• Advanced Colorectal Cancer Meta-Analysis Project. Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic col-orectal cancer. J Clin Oncol 1994; 12: 960–969.
   Google Scholar
• Mauritz R, Schwabe W, Noordhuis P, Smid K, McLeod HL, Behnke D, et al. Comparison of mRNA expression levels determined with Tag-man and competitive template RT-PCR. Nucleosides, Nucleotides & Nucleic Acids, 2004; in press
   Google Scholar
• Smorenburg C, Peters GJ, Van Groeningen CJ, Noordhuis P, Dercksen W, Loves W, et al. First line tailored chemotherapy in advanced colorectal cancer (ACRC) with 5-fluorouracil/leucovorin (5FU/LV) or oxaliplatin/irinotecan cho-sen by the expression of thymidylate synthase (TS) and dihy-dropyrimidine dehydrogenase. Proc ASCO Annual Meeting 2004: Abstract 3624.
   Google Scholar
• Becouarn Y, Gamelin E, Coudert B, Negrier S, Pierga JY, Raoul JL, et al. Randomized multicenter phase II study comparing a combination of fluorouracil and folinic acid and alternating irinotecan and oxaliplatin with oxaliplatin and irinotecan in fluorouracil-pretreated metastatic colorectal can-cer patients. J Clin Oncol 2001; 19: 4195–4201.
   PubMed Web of Science ®Google Scholar
• Wasserman E, Sutherland W, Cvitkovic E. Irinotecan plus oxaliplatin: a promising combination for advanced col-orectal cancer. Clin Colorectal Cancer 2001; 1: 149–53.
   PubMedGoogle Scholar
• Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21: 60–65.
   PubMed Web of Science ®Google Scholar